Studies have suggested the role of melanocyte-specific T-cell responses in the pathogenesis of immunotherapy-induced vitiligo, as, for instance, T-cells that recognize common melanocyte antigens, such as Melan-A and gp100, have been detected in the peripheral blood and skin lesions of patients with melanoma-associated vitiligo [89]. This evidence concerns the gene MLANA and vitiligo.